^
    1year
    Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation (ASH 2023)
    CD33 is a preferential target for AML CAR T cell therapy as it is expressed on the majority (>80%) of AML blasts and because prior clinical experience with gemtuzumab ozogamicin (GO; tradename: MylotargTM) has demonstrated the safety and efficacy of targeting CD33...Patients will receive lymphodepletion on days -5 to -2 with fludarabine (total 120 mg/m2) and cyclophosphamide (total 1000 mg/m2) followed by infusion of VCAR33 on Day 0...*NCT number pending. Clinical trial information submitted to CT.gov on July 19, 2023.
    Clinical • P1/2 data
    |
    CD33 (CD33 Molecule)
    |
    cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • fludarabine IV • VCAR33ALLO • Zamyl (lintuzumab)
    1year
    Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Vor Biopharma | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    VCAR33ALLO
    over1year
    Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, Vor Biopharma
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    VCAR33ALLO